Lyndon Lien - Aug 27, 2021 Form 4 Insider Report for Kindred Biosciences, Inc. (KIN)

Role: Director
Signature: /s/ Lyndon Lien
Stock symbol: KIN
Transactions as of: Aug 27, 2021
Transactions value $: -$195,990
Form type: 4
Date filed: 8/30/2021, 02:40 PM

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KIN	Stock Option (right to buy)	Disposed to Issuer	-$196K	-47K	-100%	$4.17	0	Aug 27, 2021	Common Stock	47K	$5.08	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Lyndon Lien is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id	Content
F1	This option provided for vesting in four equal quarterly installments from the option grant date. Pursuant to the agreement and plan of merger, dated as of June 15, 2021, by and among the Elanco Animal Health Incorporated, Knight Merger Sub, Inc., and Kindred Biosciences, Inc. (the "Merger Agreement"), the unvested portion of this option was subject to acceleration of vesting. This option was cancelled pursuant to the Merger Agreement in exchange for a cash payment of $195,990.00, representing the difference between the per share exercise price of the option and the merger consideration of $9.25 per share.

Content

This option provided for vesting in four equal quarterly installments from the option grant date. Pursuant to the agreement and plan of merger, dated as of June 15, 2021, by and among the Elanco Animal Health Incorporated, Knight Merger Sub, Inc., and Kindred Biosciences, Inc. (the "Merger Agreement"), the unvested portion of this option was subject to acceleration of vesting. This option was cancelled pursuant to the Merger Agreement in exchange for a cash payment of $195,990.00, representing the difference between the per share exercise price of the option and the merger consideration of $9.25 per share.